HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling.

AbstractINTRODUCTION:
Recent studies on CD19-specific chimeric antigen receptor (CAR)-modified T cells (CARTs) have demonstrated unprecedented successes in treating refractory and relapsed B cell malignancies. The key to the latest CART therapy advances can be attributed to the improved costimulatory signals in the CAR design.
METHODS:
Here, we established several novel CARs by incorporating T cell signaling domains of CD28 in conjunction with intracellular signaling motif of 4-1BB, CD27, OX40, ICOS, and IL-15Rα. These novel CARs were functionally assessed based on a simple target cell killing assay.
RESULTS:
The results showed that the CD28/IL-15Rα co-signaling (153z) CAR demonstrated the fastest T cell expansion potential and cytotoxic activities. IL-15 is a key cytokine that mediates immune effector activities. The 153z CARTs maintained prolonged killing activities after repetitive rounds of target cell engagement. Consistent with the enhanced target killing function, the 153z CARTs produced increased amount of effector cytokines including IFN-γ, TNFα and IL-2 upon interaction with the target cells.
CONCLUSION:
In a follow-up clinical study, an acute lymphoblastic leukemia (ALL) patient, who experienced multiple relapses of central nervous system leukemia (CNSL) and failed all conventional therapies, was enrolled to receive the CD19-specific 153z CART treatment. The patient achieved complete remission after the 153z CART cell infusion. The translational outcome supports further investigation into the safety and enhanced therapeutic efficacy of the IL-15Rα-modified CART cells in cancer patients.
AuthorsSushmita Nair, Jing-Bo Wang, Shih-Ting Tsao, Yuchen Liu, Wei Zhu, William B Slayton, Jan S Moreb, Lujia Dong, Lung-Ji Chang
JournalCurrent gene therapy (Curr Gene Ther) Vol. 19 Issue 1 Pg. 40-53 ( 2019) ISSN: 1875-5631 [Electronic] United Arab Emirates
PMID30444200 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright© Bentham Science Publishers; For any queries, please email at [email protected].
Chemical References
  • CD19-specific chimeric antigen receptor
  • Cytokines
  • Interleukin-15 Receptor alpha Subunit
  • Receptors, Antigen, T-Cell
  • Toll-Like Receptor 9
Topics
  • Adult
  • Case-Control Studies
  • Cells, Cultured
  • Cytokines (metabolism)
  • Humans
  • Immunotherapy (methods)
  • Interleukin-15 Receptor alpha Subunit (genetics, immunology)
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (genetics, immunology, therapy)
  • Receptors, Antigen, T-Cell (genetics, immunology)
  • T-Lymphocytes (immunology, transplantation)
  • Toll-Like Receptor 9 (genetics, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: